PI3K/AKT/mTOR信号通路抑制剂在卵巢癌治疗中的研究进展

卵巢癌是女性生殖系统最致命的恶性肿瘤。目前,针对卵巢癌的规范治疗方案是肿瘤细胞减灭术辅以紫杉醇/铂类联合化疗,然而大多数晚期卵巢癌患者最终因对化疗药物耐药而复发。PI3K/AKT/m TOR信号通路作为一条重要的原癌基因通路,在卵巢癌中激活并在卵巢癌的增殖、侵袭、细胞周期进程、血管形成及耐药中发挥着重要的作用,抑制该通路是卵巢癌的一个潜在治疗方法。对PI3K/AKT/m TOR信号通路抑制剂在卵巢癌治疗中的研究进展进行综述。

Research progress on PI3K/AKT/mTOR signaling pathway inhibitors in treatment of ovarian cancer

Ovarian cancer remains the leading cause of death in gynecologic malignancies. The current standard treatment for ovarian cancer includes radical surgery and platinum or taxane-based chemotherapy. However, most advanced ovarian cancer patients eventually relapse due to drug resistance to chemotherapy. As such, the search for more effective anti-ovarian cancer agents is urgent. The PI3K/AKT/mTOR pathway is thought to be one of the most important oncogenic pathways in human cancer. An increasing body of evidence has shown that this pathway is frequently hyperactivated in ovarian cancer and contributes to disease initiation and development, including proliferation, invasion, cell cycle progression, angiogenesis, and chemo-resistance. Inhibition of this pathway through small molecule compounds represents an attractive potential therapeutic approach for ovarian cancer. Therefore, research progress on PI3K/AKT/mTOR signaling pathway inhibitors in treatment of ovarian cancer is reviewed in this paper.